US FDA Approves AbbVie Drug to Treat Rare Form of Lung Cancer
The FDA also approved the VENTANA MET (SP44) RxDx Assay (Roche Diagnostics). This test serves as a companion diagnostic to help detect c-Mer protein overexpression in patients with non-squamous NSCLC who might be eligible for treatment with Emrelis.
Read The Full Blog:
https://www.coherentmarketinsights.com/news/us-fda-approves-abbvie-drug-to-treat-rare-form-of-lung-cancer-1254
The FDA also approved the VENTANA MET (SP44) RxDx Assay (Roche Diagnostics). This test serves as a companion diagnostic to help detect c-Mer protein overexpression in patients with non-squamous NSCLC who might be eligible for treatment with Emrelis.
Read The Full Blog:
https://www.coherentmarketinsights.com/news/us-fda-approves-abbvie-drug-to-treat-rare-form-of-lung-cancer-1254
US FDA Approves AbbVie Drug to Treat Rare Form of Lung Cancer
The FDA also approved the VENTANA MET (SP44) RxDx Assay (Roche Diagnostics). This test serves as a companion diagnostic to help detect c-Mer protein overexpression in patients with non-squamous NSCLC who might be eligible for treatment with Emrelis.
Read The Full Blog:
https://www.coherentmarketinsights.com/news/us-fda-approves-abbvie-drug-to-treat-rare-form-of-lung-cancer-1254
0 Comments
0 Shares
20 Views
0 Reviews
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek